Although the proportion of triple-negative breast cancers (TNBCs) diagnosed among older women is low, the number of TNBC cases is substantial because of the high incidence of breast cancer after the age of 65 years. The molecular features of TNBC in this age group have not been well described. METHODS: This study examined a population-based cohort of women with stage I to III TNBC diagnosed between the ages of 25 and 91 years with the PAM50 gene expression subtyping assay. The concordance between the TNBC classification by immunohistochemistry and the gene expression classification by PAM50, the expression of individual genes, and 5-year recurrence and breast cancer mortality in older women (≥65 years old) and younger women (<50 years old) was assessed. RESULTS: The molecular subtype distribution in TNBC was significantly different according to the age at diagnosis. TNBC was more likely to be classified as basal-like in women younger than 50 years (sensitivity, 0.91; 95% confidence interval, 0.77-0.97) than women 65 years old or older (sensitivity, 0.72; 95% confidence interval, 0.48-0.87); 35% of clinical TNBC cases in the latter group were the human epidermal growth factor receptor 2 (HER2)-enriched subtype by molecular classification. Older women with TNBC also had significantly higher expression of ERBB2 and lower expression of all 10 proliferation-associated genes tested (P < .01). The risk of breast cancer death within 5 years was significantly higher in women with TNBC in comparison with women with hormone receptor-positive cancers in all age groups. CONCLUSIONS: This study revealed differences in molecular subtypes among clinical TNBC cases based on patient age. A potentially targetable HER2-enriched group raises the possible need for intrinsic subtyping in older women with TNBC. Cancer 2018;124:4676-4684. © 2018 American Cancer Society.
INTRODUCTION
The population of the United States is aging, with approximately 20% of the population (approximately 70 million people) expected to be older than 65 years by 2030. 1 The incidence of breast cancer increases with age, and this has resulted in a high percentage of women with breast cancer being older than 65 years. 2 Forty-five percent of all women diagnosed with breast cancers in the United States in 2014 were 65 years old or older, and the proportion is projected to be half by the year 2030. 3, 4 However, much of the understanding of breast cancer treatment is based on trials in which older women are underrepresented or excluded by design. [4] [5] [6] [7] Breast cancers among older women typically have a less aggressive biology because of a higher percentage of hormone receptor-positive tumors or a higher proportion of the luminal subtype, a lower proliferation rate, and lower grade tumors in comparison with younger women with breast cancer. 2, 4, 8, 9 Patterns of molecular gene expression and genetic mutations also differ between breast cancers diagnosed in younger women and older women. 8, 10 These differences in breast tumor biology according to age may have implications for treatment and survival. 2, 4, 11 Triple-negative breast cancers (TNBCs), lacking expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2)/neu, have a poor prognosis and present a particular treatment challenge because there are no targeted therapies available. The triple-negative (TN) phenotype is a frequent feature of breast cancers among women aged 35 years or younger, with approximately one-third of breast cancers in this age group being TN. Even though a smaller proportion of breast cancers diagnosed among older women are TN, 12 the number of TNBCs in this age group is substantial because of the high incidence of breast cancer in older women.
TNBC, based on clinically determined estrogen receptor, progesterone receptor, and HER2 protein expression and/or gene amplification, is considered a reasonable surrogate for the basal-like gene expression subtype, but the correlation of the TN phenotype and the basal-like subtype is not perfect, with an average positive predictive value of 70%. 13, 14 Furthermore, the classification accuracy of a clinical TN status for the basal-like subtype of breast cancer may not be uniform across age groups.
Cancer December 15, 2018 Using PAM50, a Food and Drug Administrationapproved quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) intrinsic subtyping tool that assays the expression of 50 genes, we examined molecular subtypes and gene expression in a population-based cohort of women with breast cancer. 13, 16 To our knowledge, no study has previously compared molecular subtypes and gene expression patterns of TNBC in older women versus younger women. Here we describe the classification accuracy of a clinical TN status for the basal-like molecular subtype of breast cancer for older ages at diagnosis versus younger ages, and we identify potential differences in the gene expression patterns of TNBC.
MATERIALS AND METHODS

Study Population
The study population consisted of women with breast cancer from the Life After Cancer Epidemiology (LACE) and Pathways studies. 17 LACE participants were women with early-stage breast cancer (American Joint Committee on Cancer stage I with a tumor size ≥ 1.0 cm, stage II, or stage IIIA) who were between the ages of 25 and 79 years at the time of diagnosis in 1996-2000, had completed chemotherapy and/or radiation therapy at the time of their entry into the cohort, and were within 39 months of their diagnosis. The patients were required to be free of cancer and to have had no other cancer diagnosis within the previous 5 years. The patient characteristics and study methods of the LACE study have been described elsewhere. 18 The Pathways study included women who were 25 to 91 years old and had been diagnosed with invasive breast cancer from 2005 to 2013 (for this study, only women diagnosed through 2008 were included) in Kaiser Permanente Northern California with no other prior history of cancer. Women enrolled in the Pathways study were enrolled within 2 months of their diagnosis (mean time, 1.8 mo; maximum time, 7.2 mo). Details of the Pathways study have been previously described. 19 All participants provided informed consent, which was approved by the Kaiser Permanente Northern California and University of Utah institutional review boards. Patient and tumor characteristics at the time of diagnosis, including age, American Joint Committee on Cancer disease stage, tumor size, lymph node status, histologic grade, hormone receptor status, and HER2 overexpression/gene amplification of the primary tumors, were obtained from medical records and tumor registries. Hormone receptors were determined according to current guidelines at the time of diagnosis (from 1996 to 2013) and were coded as positive or negative. Patients with a tumor size < 1.0 cm, patients with bilateral disease, and patients who received neoadjuvant therapy were excluded from the PAM50 assay.
From a cohort of more than 3000, a stratified sample was selected for the PAM50 molecular subtyping study; it included all patients with HER2-positive and TN cancers and 18% of hormone receptor-positive, HER2-negative patients. The cohort was followed for recurrence and survival through August 2012. Patient outcomes were ascertained by self-report, cancer registry follow-up, and linkage to medical records.
Formalin-fixed, paraffin-embedded tissue blocks, hematoxylin-eosin-stained slides, and pathology reports were obtained from the institutions where the primary surgery was performed. The proportion of subjects for whom tissue samples were not obtained was less than 10%, as described previously. 17 One pathologist (R.E.F.) reviewed the hematoxylin-eosin-stained slides and circled the representative tumor on the slide. One or 2 tissue punches were obtained for the PAM50 assay.
Gene Expression Assay and Subtype Classification
TN categorization was based on clinical immunohistochemistry (IHC) testing for estrogen receptor and progesterone receptor and IHC and/or fluorescence in situ hybridization testing for HER2. This information was gathered from medical records and the tumor registry. For molecular subtyping, tissue punches obtained from formalin-fixed, paraffin-embedded samples were deparaffinized, and the tissue was digested for RNA extraction as described elsewhere.
13 PAM50 testing was performed by qRT-PCR for 50 genes. A no-template sample and reference DNA samples were used for negative and positive quality controls, respectively, for each test and for 5 housekeeping genes. 13 Laboratory personnel were provided only study-identifying numbers for tracking the specimen and were blinded to clinical characteristics. Each batch of tissue sent for PAM50 assays included a mixture of different clinical pathological types of breast cancers. Algorithms were used to classify intrinsic subtypes-luminal A, luminal B, HER2-enriched, basallike, and normal-like-as described elsewhere. 16 
Survival
Incident breast cancer metastasis, recurrence, and a second primary breast cancer diagnosis during follow-up were ascertained by self-report and record linkage and were verified by medical record review. Cancer as the Cancer December 15, 2018 cause of death was determined from death certificates, which were supplemented with medical records if necessary. The outcomes for the survival analysis were a new breast cancer event, which was defined as a first recurrence/metastasis or a new primary breast cancer (called a recurrence), and breast cancer death. The time scale for the survival analysis was the time since diagnosis; this allowed for delayed entry into the cohort (ie, left truncation) because of the enrollment of individuals into the cohort studies up to 3 years after their diagnosis.
Statistical Analysis
Distributions of clinical and pathological characteristics among women with TN phenotypes were compared by age and were compared with other phenotypes in the subcohort. We estimated percentage distributions across categories and tested for significance with chi-square tests. The analysis incorporated the original sampling weights and the stratified sampling design for an unbiased estimation of population parameters and valid estimates of standard errors with svy commands in Stata software (StataCorp).
We calculated sensitivity, specificity, and positive predictive values and assessed the ability of a clinically determined TN status to correctly classify the PAM50 basal-like subtype as the gold standard within age categories. The prevalence of the TN and basal-like phenotype differs by race/ethnicity, and racial/ethnic minority populations have different age distributions. Therefore, sensitivity and specificity were also calculated and stratified by race/ethnicity.
We examined variations in several continuous variables, including the Pearson correlation to the basal-like centroid from the training set, the proliferation score, the relative expression of genes defining the TN phenotype ( 13 First, we calculated the mean and standard deviation for each of these variables within 3 age groups of TN tumors. Second, adjusting for race/ ethnicity, we tested for the significance of the trend in relative expression with age in a linear regression model.
Hazard ratios and 95% confidence intervals for the associations of the clinical subtype with outcomes were estimated from Cox proportional hazards models, with adjustments made for demographic variables (age at diagnosis and race/ethnicity) and other tumor characteristics at diagnosis (tumor size, number of positive nodes, and grade). Analyses accounted for the case-cohort study design and the stratified sampling of the subcohort. 17 Previous analyses showed that the influence of the tumor subtype on survival was most evident during the first 5 years after diagnosis; therefore, the analysis was focused on that time period. 17 
RESULTS
The 2 cohorts (Pathways and LACE studies) included women diagnosed with breast cancer between the ages of 25 and 91 years, with the largest proportion of women between the ages of 50 and 59 years. The 1319 cases with PAM50 assay results were similar to the parent cohorts with respect to clinical characteristics, patient age, and race/ethnicity. 8 The proportion of patients with TNBC, as defined by clinical tests, who were white and non-Hispanic increased with age in a similar manner to the other phenotypes ( Table 1 ). The histologic grade of poorly differentiated or undifferentiated tumors predominated among women diagnosed with TNBC before the age of 50 years (86%) but was somewhat less prevalent (71%) among TNBCs in the older age groups. The frequency of large tumors in the ≥2-to 5-cm size category was higher among TNBC patients than non-TNBC patients in each age group. Among TNBC patients, there was no indication that older women had a higher frequency of large tumors than younger women.
The proportion of both TNBCs and basal-like breast cancers among women ≥65 at diagnosis was lower than the proportion in the younger age group ( Table 2) . The sensitivity and positive predictive value of the clinically determined TN phenotype for correctly classifying a breast cancer as the basal-like intrinsic subtype as determined by PAM50 decreased with age ( Table 2 ). The trends of a lower prevalence of the TN phenotype and a lower positive predictive value for the basal-like subtype with older age appeared to be present within subgroups by race/ethnicity, although because of the small numbers within some age-race categories, statistical power was limited. The proportion of basal-like cancers for each age group was examined within subgroups by race and ethnicity. The basal-like proportion declined with Cancer December 15, 2018 age among white non-Hispanics, among Hispanics, and among Asians and Pacific Islanders. For black or African American women, the proportion of basal-like cancers remained relatively high (≥25%) for all age groups (Table 2 ).
PAM50 subtypes were significantly different among different age groups with TNBC (P < .001; Fig.  1 ). Eighty-seven percent of TNBCs diagnosed in women younger than 50 years were of the basal-like subtype, whereas this ratio was only 52% in women ≥65 years. The HER2-enriched subtype was observed in 35% of women ≥65 years and in 10% of women younger than 50 years. The molecular expression of ESR1 and PGR did not vary significantly by the age at diagnosis among women with TNBC after adjustments for race and ethnicity (Fig. 2) . The expression of ERBB2 was positively associated with age (P = .02). When the expression of proliferation-associated genes among women with TNBC was evaluated, age was inversely associated with the proliferation score (average of the 10-gene signature) and with each proliferation gene individually (P < .01) after adjustments for race and ethnicity (Fig. 3) . We repeated the analysis of gene expression by the age at diagnosis after restricting the sample to tumors confirmed to be basal-like by PAM50 (data not shown). Within the basal-like sample, there was no association between age and the expression of ESR1, Cancer December 15, 2018 PGR, or ERBB2. Among basal-like tumors, trends for proliferation genes were in the same direction as those shown in Figure 3 among TNBCs: higher expression of proliferation genes was associated with younger age. However, the associations between age and proliferation gene trends were attenuated and were statistically significant for only 3 of the genes (CEP55, P = .01; MYBL2, P = .005; and KIF2C, P = .02). When the survival of women with the TN tumor phenotype was compared with the survival of women with hormone receptor-positive breast cancer in the same cohort, TNBC was associated with an increased risk of breast cancer recurrence and breast cancer death in the first 5 years after diagnosis in all age groups (Fig.  4 and Table 3 ). The association between TNBC and survival was independent of tumor stage and grade. When the period of follow-up was extended to the end of study follow-up, hazard ratios for TNBC were attenuated but remained significant for recurrence in the age group of patients 65 years old or older (hazard ratio, 1.91; 95% confidence interval, 1.03-3.54). Among women diagnosed when they were 65 years old or older, the association between TNBC and adverse breast cancer outcomes was more apparent in those women with tumors confirmed as basal-like by PAM50.
DISCUSSION
It has long been postulated that breast cancers among older women have less aggressive characteristics, including a higher rate of hormone receptor-positive tumors, a lower histologic grade, and a lower proliferation rate. 2, 4 Although TNBCs are less prevalent among older women, TN/basal-like cancers are still diagnosed in significant numbers because of the higher incidence of breast cancers overall in this age group. In this study, poor prognostic factors such as poor and undifferentiated cancers, larger tumor size, and higher number of positive lymph nodes were more frequent among younger women both in TN and other phenotypes combined. The prevalence of both clinically determined TNBCs and qRT-PCR (PAM50)-determined basal-like cancers were lower among women diagnosed with breast cancer at age 65 and older. The sensitivity and positive predictive value of a clinical TN status for classifying the basal-like molecular subtype also decreased with age. The prevalence of TN and basallike breast cancers varies by race/ethnicity, and minority populations have different age distributions of breast cancer. The proportion of TN and basal-like cancers was highest among African American women, although the TN phenotype was least sensitive in predicting the basallike subtype in this racial group. There was a significant difference in molecular subtypes among older and younger women. Only 52% of the women ≥65 years with TNBC at the time of diagnosis had the basal-like molecular subtype, whereas 87% of the women younger than 50 years at diagnosis did. Thirty-five percent of TNBCs seen in women ≥65 years were the HER2-enriched subtype. Among women with TNBC, approximately 20% to 30% have the non-basal-like molecular type. 20 In this study, the proportion of non-basal-like tumors, especially HER2-enriched cancers, was found to be significantly higher among older women, who may benefit from targeted therapies. Postmenopausal women with hormone-positive metastatic breast cancer of the clinical HER2-negative/molecular HER2-enriched subtype have been shown to benefit from HER2-targeted (lapatinib) therapy. 21 Androgen receptor (AR) messenger RNA is highly expressed in both luminal and HER2-enriched molecular subtypes of TNBC. The luminal/androgen receptor (LAR) subtype, though estrogen receptor-negative, has hormonally regulated pathways, including androgen/estrogen metabolism. LAR TNBCs have lower proliferation rates than other TNBC subtypes, and this results in relative chemoresistance in a neoadjuvant setting. 22 The percentage of tumor cells positive for AR by IHC is significantly higher in the LAR subtype than other subtypes within TNBCs. AR has been the focus of therapeutic targets in adjuvant and neoadjuvant settings in recent and ongoing clinical trials. 23, 24 AR is not among the genes included in PAM50, and we did not have access to tissue blocks to perform IHC for AR to test whether the increase in the HER2-encriched subtype in older patients correlates with the LAR subtype.
ESR1 and PGR gene expression levels were similar in younger and older women with TNBC and are unlikely to have contributed to the difference in the Cancer December 15, 2018 sensitivity of predicting the basal-like molecular type in these age groups. ERBB2 expression was higher among older women. TNBCs are a diverse group of cancers with nonuniform responses to therapy. 25 Some significant differences between older and younger women with TNBC have been described. In studies using IHC staining, older women with TNBC were reported to have a higher frequency of cytokeratin 5/6 expression, lower expression of EGFR, 9,12 a lower rate of Ki67 labeling index and cytokeratin 7/8 positivity, and a higher rate of Bcl2 and cytokeratin 18 positivity. 9 In this study, we used different methods (ie, qRT-PCR) and evaluated a set of 10 proliferation-related genes: ANLN, CDC20, CENPF, CEP55, KIF2C, RRM2, UBE2C, MKI67, CCNB1, and MYBL2. These proliferation genes correlate with Ki67 expression, and the last 4 genes are also included in the set of genes of commonly used, commercially available Oncotype DX testing. We observed that all 10 proliferation genes had significantly lower expression among older women with TNBC. This result is consistent with the IHC-based studies in that it indicates that lower proliferation is characteristic of TN tumors from older women.
Several characteristics of TNBC in the population of women diagnosed at an age of 65 years or older versus younger women documented here, including a lower grade distribution, a lower predictive value of clinical TNBC for the molecular basal-like subtype, and lower expression of proliferation genes, are suggestive of prognostic differences for TNBC by age group. However, when we accounted for tumor size, nodes, and grade, TNBC remained associated with breast cancer recurrence and death in elderly women. Hazard ratios in the age group diagnosed at an age of 65 years or older indicated that the worse survival outcomes were more apparent in those TNBCs confirmed as the basal-like molecular subtype, but the numbers of outcomes after subgrouping by age and PAM50 results were small, and this limited our ability to distinguish different survival patterns among these groups. The higher rates of recurrence and breast cancer deaths among the youngest women with non-basal-like TNBC versus basal-like TNBC are likely due to a lower response to chemotherapy due to lower proliferative rates and/or lower proliferation-associated gene expression levels. Although we do not have treatment information, it is likely that a significant proportion of the patients younger than 50 years, if not all, received systemic therapy after the diagnosis of TNBC.
TNBC is a heterogeneous breast cancer that has been further subclassified into 4 molecular subtypes with significantly different responses to similar neoadjuvant therapy. 25, 26 There is interest in developing targeted treatment for these subclassifications. Although the genes assayed in our study did not include all genes needed to define the subclasses of basal-like cancers, our findings indicate that age is a determinant of some of the heterogeneity among TNBCs. Our findings of higher ERBB2 expression and lower proliferation-related gene expression raise the possible need for intrinsic subtyping in older women with TNBC when the benefits of systemic chemotherapy are questionable or when potential targetable therapies become available for specific molecular subclassifications of TNBC.
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